CX3CR1 and ovarian carcinoma: Collectively, our data suggest that impairment of CX3CR1 in ovarian carcinoma could be beneficial from multiple standpoints: (1) it could disrupt FA uptake, further depriving growth of rapidly proliferating metastatic ovarian cancer cells, and, most importantly, (2) it could increase efficacy of DNA damage agents, including x-ray radiation and cisplatin.